{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:26:35Z","timestamp":1789928795973,"version":"4.0.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1097\/ftd.0000000000000268","type":"journal-article","created":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T04:36:30Z","timestamp":1450672590000},"page":"230-238","source":"Crossref","is-referenced-by-count":12,"title":["In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia"],"prefix":"10.1097","volume":"38","author":[{"given":"Karin","family":"Skoglund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Olsson-Str\u00f6mberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Bergquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warunika","family":"Aluthgedara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. J. Kumari A.","family":"Ubhayasekera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svante","family":"Vikingsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Svedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"S\u00f6derlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sandstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Johnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Aagesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Alsenhed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"H\u00e4gg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curt","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kourosh","family":"Lotfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Gr\u00e9en","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210129","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":". Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"R2-6-20210129","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":". Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"R4-6-20210129","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib.","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R5-6-20210129","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1124\/dmd.109.031302","article-title":". Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.","volume":"38","author":"Dohse","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"R6-6-20210129","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.leu.2404897","article-title":"Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2.","volume":"22","author":"Shukla","year":"2008","journal-title":"Leukemia"},{"key":"R7-6-20210129","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":". Active transport of imatinib into and out of cells: implications for drug resistance.","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"R8-6-20210129","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s11095-007-9254-z","article-title":"Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications.","volume":"24","author":"Koepsell","year":"2007","journal-title":"Pharm Res"},{"key":"R9-6-20210129","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1073\/pnas.84.21.7735","article-title":". Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.","volume":"84","author":"Thiebaut","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R10-6-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425255.4.1.1","article-title":"ABCG2: structure, function and role in drug response.","volume":"4","author":"Polgar","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R11-6-20210129","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":". Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"R12-6-20210129","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":". Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"R13-6-20210129","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":". Genetic contribution to variable human CYP3A-mediated metabolism.","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"R14-6-20210129","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF02353475","article-title":"Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.","volume":"24","author":"Wilkinson","year":"1996","journal-title":"J Pharmacokinet Biopharm"},{"key":"R15-6-20210129","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00228-009-0772-y","article-title":". CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity.","volume":"66","author":"Green","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"R16-6-20210129","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":". Harmonization of molecular monitoring of CML therapy in Europe.","volume":"23","author":"Muller","year":"2009","journal-title":"Leukemia"},{"key":"R17-6-20210129","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":". Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"R18-6-20210129","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":". Tolerability-adapted imatinib 800 mgd versus 400 mgd versus 400 mgd plus interferon-alpha in newly diagnosed chronic myeloid leukemia.","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"R19-6-20210129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00228-003-0575-5","article-title":". Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.","volume":"59","author":"Mirghani","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"R20-6-20210129","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00228-006-0230-z","article-title":". Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.","volume":"63","author":"Allqvist","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R21-6-20210129","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/01.fpc.0000230411.89973.1b","article-title":". CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population.","volume":"16","author":"Mirghani","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R22-6-20210129","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1124\/jpet.103.054841","article-title":". Developmental expression of the major human hepatic CYP3A enzymes.","volume":"307","author":"Stevens","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R23-6-20210129","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0378-4347(00)00577-6","article-title":". Simultaneous determination of quinine and four metabolites in plasma and urine by high-performance liquid chromatography.","volume":"754","author":"Mirghani","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R24-6-20210129","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1570-0232(03)00206-X","article-title":". Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma.","volume":"791","author":"Parise","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R26-6-20210129","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/03602530701690374","article-title":". Drugs as CYP3A probes, inducers, and inhibitors.","volume":"39","author":"Liu","year":"2007","journal-title":"Drug Metab Rev"},{"key":"R27-6-20210129","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","article-title":". Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.","volume":"116","author":"Ingelman-Sundberg","year":"2007","journal-title":"Pharmacol Ther"},{"key":"R28-6-20210129","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00008571-200310000-00003","article-title":". Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.","volume":"13","author":"Floyd","year":"2003","journal-title":"Pharmacogenetics"},{"key":"R29-6-20210129","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbrc.2005.09.020","article-title":". Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles.","volume":"338","author":"Rodriguez-Antona","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"R30-6-20210129","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/00008571-200112000-00006","article-title":". In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration.","volume":"11","author":"Lin","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R31-6-20210129","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0009-9236(98)90175-8","article-title":". Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam.","volume":"64","author":"Kashuba","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"R32-6-20210129","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/0091270003262101","article-title":". Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion.","volume":"44","author":"Peng","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"R33-6-20210129","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2125.1993.tb05698.x","article-title":"The reproducibility of quinine bioavailability.","volume":"35","author":"Paintaud","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"R34-6-20210129","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s002280050646","article-title":". Grapefruit juice has no effect on quinine pharmacokinetics.","volume":"55","author":"Ho","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"R36-6-20210129","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3324\/haematol.2011.056457","article-title":". Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.","volume":"97","author":"White","year":"2012","journal-title":"Haematologica"},{"key":"R37-6-20210129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10038-006-0087-0","article-title":". Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.","volume":"52","author":"Shikata","year":"2007","journal-title":"J Hum Genet"},{"key":"R38-6-20210129","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/FPC.0b013e3283561666","article-title":". Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.","volume":"22","author":"Tarasova","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"R39-6-20210129","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/FPC.0000000000000022","article-title":". Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.","volume":"24","author":"Skoglund","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"R40-6-20210129","first-page":"63","article-title":". ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro.","volume":"6","author":"Skoglund","year":"2013","journal-title":"Pharmgenomics Pers Med"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000268","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:30:07Z","timestamp":1620952207000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201604000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000268","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}